首页> 美国卫生研究院文献>World Journal of Gastroenterology >Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient
【2h】

Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient

机译:肌萎缩性侧索硬化症患者接受马赛替尼治疗期间的自身免疫性肝炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report a case of acute severe hepatitis resulting from masitinib in a young amyotrophic lateral sclerosis patient. Hepatotoxicity induced by masitinib, a tyrosine kinase inhibitor, is usually transient with mild elevation of transaminases, although acute hepatitis has been not reported to date. The hepatitis was resolved after masitinib was discontinued and a combination of prednisone and azathioprine was started. The transaminases returned to baseline normal values five months later. This is the first case in the hepatitis literature associated with masitinib. The autoimmune role of this drug-induced liver injury is discussed. Physicians should be aware of this potential complication.
机译:我们报告了一名年轻的肌萎缩性侧索硬化症患者因masitinib导致的急性重症肝炎病例。尽管迄今尚未报道急性肝炎,但酪氨酸激酶抑制剂马赛替尼诱导的肝毒性通常是短暂的,转氨酶轻度升高。停用马赛替尼并开始联合泼尼松和硫唑嘌呤后,肝炎得到解决。 5个月后转氨酶恢复到基线正常值。这是与马赛替尼相关的肝炎文献中的第一例。讨论了这种药物诱导的肝损伤的自身免疫作用。医师应意识到这种潜在的并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号